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Abstract 
Despite the great promise that many potential neuroprotective agents have shown in the 
laboratory, to date these have not translated to positive results in patients with Parkinson’s 
disease  (PD), with several recent high profile clinical trials (Coenzyme Q10, Creatine, 
Cogane among others) all failing to show any clinical benefits.  This “failure to translate” is 
likely related primarily to our incomplete understanding of the pathogenic mechanisms 
underlying PD together with excessive reliance on data from the toxin-based animal models 
of PD to judge which agents to take to double blind clinical trial evaluation.  In addition 
restricted resources inevitably mean difficult compromises must be made in terms of optimal 
trial design, made harder by the absence of validated biomarkers of disease progression.  
To date, drug development in PD dementia has been mostly unsuccessful; however, 
emerging biochemical, genetic and pathological evidence suggests a link between tau and 
A-Beta deposition and cognitive decline in PD – potentially opening up new targets for 
therapeutic intervention. In this context, this review discusses some of the most important 
existing current and future potential therapeutic agents for motor and cognitive impairments 
on the horizon to help inform whether there is greater reason to expect positive results in the 
short or medium term future.   
 
Key Points 
 Currently obstacles impeding the development of effective neuroprotective therapies 
for PD include a lack of understanding regarding the pathogenesis of PD, lack of 
accurate animal models of PD, limitations in clinical trial design, insensitive trial 
endpoints, a lack of validated biomarkers and inhibitory costs of developing new 
drugs. 
 Advances in the development of transgenic animal models, newer adaptive and 
delayed start trial designs, identification of possible serum, CSF or neuroimaging 
biomarkers and re-positioning of existing drugs for use in PD are making inroads to 
the goal of identifying and testing an effective disease modifying therapy. 
 Alpha-synuclein plays a key role in the pathogenesis of PD and targeting the 
formation and clearance of this protein by directly blocking alpha synuclein 
aggregation, enhancing lysosomal clearance systems or immunisation against alpha-
synuclein show promising results in pre-clinical models but are still very early in 
development. 
 As 50% of PDD patients have comorbid AD pathology which can confer a worse 
prognosis, targeting tau and AB may be useful avenues to attempt to reduce or halt 
cognitive dysfunction, and disease modifying therapies under investigation in AD may 
also be of benefit in PD. 
 
Introduction 
Despite the obvious need for neuroprotective or disease modifying agents and the great 
promise many potential candidates have shown in preclinical studies, there are currently no 
treatments that have been licensed as neuroprotective agents in Parkinson’s disease (PD).  
Several high profile phase I/II clinical trials of notable potential neuroprotective agents have 
recently failed to show benefits despite strong laboratory and in vivo animal data seeming to 
support their potential. These are summarised in Table 1.  This discrepancy between 
encouraging preclinical data and failure of translation in clinical trials requires continuous 
reappraisal, however rather than performing an individualised analysis of why each of these 
specific agents may have failed in clinical trials, this review focuses on a general critique of 
the current obstacles that continue to impede the development of neuroprotective agents. In 
this context, we present a summary of the current status of major potential therapeutic 
candidates currently being assessed in clinical trials for neuroprotective or disease modifying 
effects in PD and assessment of their therapeutic potential.  Although clinical trials assessing 
potential disease modifying therapies have mainly focused on preserving motor function 
(historically easier to assess and because validated tools to assess non-motor symptoms 
have only relatively recently appeared); non-motor symptoms of PD, (in particular cognitive 
dysfunction), are increasingly recognised as having a significant contribution to patients’ 
quality of life, are only partially responsive to dopaminergic therapy and mostly remain 
refractory to current intervention1,2. Of specific relevance is the growing amount of evidence 
suggesting that AD-type pathology – amyloid-B plaques and hyperphosphorylated tau-
containing neurofibrillary tangles, contributes to cognitive dysfunction in PD. To this end, we 
also discuss whether targeting tau and utilising disease modifying treatments in AD to 
improve cognitive dysfunction may be of benefit to patients with PD also. 
 
Current obstacles impeding development of neuroprotective therapies in PD and 
potential solutions 
Lack of understanding regarding the pathogenesis of PD 
It is currently believed that neurodegeneration in PD is due to a combination of cell-
autonomous and non cell-autonomous processes. The cell autonomous mechanisms include 
mitochondrial dysfunction, dysfunction of the autophagy/lysosomal processes and 
dysregulation of calcium homeostasis, while non-cell autonomous processes include 
neuroinflammation, loss of trophic support and the trans-synaptic transmission of misfolded 
alpha synuclein.3,4 The interaction between these pathways remains unclear, and the long 
term impact on interfering with these fundamental processes for normal healthy cell function 
is not understood, but this process of neuronal degeneration has been speculated to occur 
in four stages: from the initial molecular prodrome, leading to cell damage, resulting in 
decompensation and dysfunction, and finally to degeneration. Elucidation of these 
pathogenetic details is facilitated by; 1) The creation of human cell lines from patients with 
the various Mendelian forms of PD, helping to explain the interactions between lysosomes, 
mitochondria and abnormal protein aggregation in single cell systems, 2) the development of 
transgenic animals with human PD genes helping to demonstrate how these processes 
impact on cell-to cell transmission of alpha synuclein.  This knowledge can identify whether 
patients at each or any stage of neurodegeneration, might gain benefit from potential “target 
specific” neuroprotective or neurorestorative therapies (for review3,5) 
 
Lack of accurate animal models: 
The most widely used animal models of PD are based on administration of locally 
administered neurotoxin 6-hydroxydopamine (6-OHDA), systemically administered toxin 1-
methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in mice and non-human primates, or 
direct infusion of bacterial endotoxin lipopolysaccharide (LPS) into the nigrostriatal pathway 
of rats to produce models of selective degeneration of substantia nigra pars compacta 
(SNpc) dopamine (DA) neurons to produce a parkinsonian syndrome.6,7 Other neurotoxins 
less often also used include rotenone, paraquat, isoquinoline derivatives, and 
methamphetamine.8 Though adequate at replicating the motor aspects of PD in the later 
stages, the very selectivity of these models means they often do not exhibit the complex 
extra-dopaminergic involvement and non-motor dysfunction seen in the early stages of PD.  
Also, the pathological hallmark of PD – the presence of Lewy bodies (LB), has not 
consistently been observed in these neurotoxin based animal models.8  Though some MPTP 
models in rhesus monkeys have been shown to mimic the extra-striatal dopamine, 
noradrenaline, and serotonin changes often observed in humans,9 these models require the 
acute administration of toxins which likely does not reflect the chronic and progressive 
nature of the neurodegenerative process in PD.  Recent refinements to this technique 
however using low concentrations or an intermittent dosing schedules are now being 
successfully used to replicate the more progressive pathology seen in humans and are also 
being used to study compensatory mechanisms10,11  
Transgenic animal models, which recapitulate monogenic mutations seen in familial PD 
patients, have an advantage over neurotoxin based models is that these models produce the 
pathological abnormalities seen in PD and provide insights into selected molecular aspects 
of PD pathogenesis and early stages of the disease - the MitoPark mouse has been 
developed in which mitochondrial function is selectively disrupted in dopaminergic neurons – 
producing a mouse exhibiting a progressive PD-like phenotype. Though not reproducing the 
genetic mutations seen in humans with PD, these models could be useful in large scale 
screening of new therapeutic agents.7  A major limitation of these models however is that 
they do not consistently reproduce the expected nigrostriatal degeneration and phenotypes 
seen in PD.12 
Due to the growing amount of evidence implicating the mis-folding of alpha synuclein as a 
key event involved in the pathogenesis of PD, new mouse models have been developed in 
which a single injection of synthetic mis-folded alpha-synuclein can initiate a cascade of 
events leading to the presence of LB-like inclusions, selective loss of neurons in the 
substantia nigra pars compacta, and motor impairments.13,14  
While it is clear that these animal models have led to great steps forward in the treatment of 
the motor symptoms and complications of PD, it is early to judge whether they will be any 
more successful in aiding the development of disease modifying or neuroprotective 
strategies.   There is currently no “best” model that perfectly captures the chronic 
neurodegeneration and clinical phenotypes seen in PD – the current animal models have 
advantages and disadvantages; to most effectively develop a neuroprotective agent in pre-
clinical trials, investigators need to understand the limitations of various models and may 
need to choose a specific model based on specific research needs or develop an agent that 
has reproducible efficacy across multiple animal models. 
 
Limitations in trial design: 
A further potential contribution to the lack of translation between encouraging results in 
preclinical models and clinical trials is the trial design. Current designs may either not be 
sensitive enough to identify disease modifying effects, or may struggle to convincingly 
separate such effects from long-lasting symptomatic relief. 
Washout trial designs attempt to eliminate and separate any potential symptomatic effects 
from disease modifying effects of the studied drug treatment; however, there often remains 
underlying uncertainty as to whether any of the beneficial effects seen could be due to 
unanticipated long lasting symptomatic effects if the washout period is too short –one 
putative explanation for levodopa’s apparent disease modifying effect in the ELLDOPA 
trial.15  However using a long washout period of several months or longer may be 
confounded by the progressive nature of PD, and risks high levels of patient drop out.   
More promising are delayed start designs, as used in the ADAGIO trial to assess rasagiline’s 
disease modifying potential, although these require an initial period long enough to allow a 
neuroprotective effect to occur (which also raises ethical concerns of drug naïve patients 
remaining on placebo for a long period), and again differential patient dropout between 
randomised groups can affect the statistical analysis of results, while the expected 
differences between the early and delayed start groups are often small due to the slowly 
progressive nature of PD.16 
To truly assess neuroprotective or disease modifying effects, a long term simple / 
longitudinal study designs is most effective - using composite global measures to provide a 
multi-dimensional assessment of disease progression over a long time period – typically a 
number of years.17  Though this is the most reliable at differentiating disease modifying 
effects on various outcomes, it requires considerable investment and extensive collaboration 
between drug companies, research institutes and clinical centres to manage the significant 
costs.  
 
Insensitive  endpoints/outcome measures of clinical trials: 
Objective endpoints in PD based on biomarkers in CSF, blood or imaging are yet to have 
documented validity and reliability, so clinical trials have to rely on clinical endpoints or 
markers by which to assess disease progression, which have numerous limitations. The time 
taken for drug naïve PD patients to require dopaminergic or symptomatic therapy as a 
specific endpoint as evidence of disease progression is often used in clinical trials, and 
although this is a well-defined, measurable endpoint, not confounded by any possible 
symptomatic effects from other drugs,18 a notable limitation is that in reality, the decision to 
start symptomatic therapy relies on a number of complex factors between the patient and the 
physician and often does not correlate with disease stage or rate of progression, and it is 
often impossible to differentiate whether delayed need for symptomatic treatment reflects 
symptomatic or neuroprotective effects of a study drug18 19 
Another commonly used method is the use of repeated assessment with the Unified PD 
rating scale (UPDRS). While also subject to intra- and inter- rater variability, the most recent 
version of this scale (MDS-UPDRS), when combined with scales to evaluate gait and 
dyskinesia and multiple other non-motor measures of cognition, mood and sleep, can 
provide multiple opportunities to detect a signal of effect, perhaps more likely to indicate 
clinically relevant advantage if all are indicating positive beneficial effects. 
 
Lack of validated biomarkers 
A validated, sensitive biomarker to diagnose PD and monitor response to therapeutic 
intervention does not currently exist, though research is ongoing.   The Parkinson’s 
Progression Markers Initiative (PPMI), have recently published encouraging results that have 
shown that levels of CSF Aβ1-42, T-tau, P-tau181, and α-synuclein have prognostic and 
diagnostic potential in early-stage PD, with lower levels seen in PD compared with health 
controls.20 Groups trying to improve upon imaging biomarkers using 7T MRI, transcranial 
ultrasound, novel MRI sequences or novel PET ligands have shown promise in 
differentiating PD patients from controls, but are still at an early stage in development.21 
 
Suboptimal patient population choice for clinical trials 
Commonly, studies have chosen to include early untreated PD patients as there is thought to 
be a higher percentage of remaining neurons that might be salvaged compared to patients 
with more advanced disease. 22 A recent study quantifying nigrostriatal degeneration in PD 
patients from time of diagnosis showed that dopamine markers in the fibres of the dorsal 
putamen are however already variably reduced at diagnosis and are virtually absent as little 
as 4 years after diagnosis.23  Any clinical deterioration after this time is thought to represent 
a loss of a compensatory mechanisms or degeneration of non-dopaminergic neurons.  This 
data has obvious implications for patient selection for future trials and may also suggest that 
previous trials with seemingly negative results may have been conducted in patients with 
little surviving dopaminergic neurons.  Ideally, patients enrolled for potential neuroprotective 
trials should be at an early enough stage of their disease so as to have a greater number of 
surviving neurons from which to derive benefit.  A caveat to this is that these patients 
typically take longer to identify, and there is a higher rate of misdiagnosis, or risk of including 
patients with atypical forms of parkinsonism such as PSP, MSA, CBD etc., while 10% of 
patients diagnosed clinically with early PD have normal dopaminergic functional imaging (so 
called SWEDDS (scans without evidence of dopaminergic deficit)24. Patients may also have 
widely different severity of disease even at presentation and have variable rates of 
progression - increasing age at onset is associated with higher levels of disability and Hoehn 
and Yahr stage, while tremor dominant PD is associated with slower disease progression 
and less cognitive impairment than patients with akinetic rigid phenotypes.25 
Conversely, including patients with moderate/advanced PD who are more likely to have 
measurable endpoints on validated scales, may have such advanced neurodegeneration 
that the effect of introducing neuroprotective agents may be too little, too late.  However, it 
has been recently shown that there is a continued persistence of populations of melanin 
containing neurons in the SNpc in comparison to the number of tyrosine hydroxylase-
immunoreactive neurons for decades after diagnosis, which may suggests that trophic or 
regenerative therapies might still have value even in the later stages of the illness.23 
In summary, although there is a little doubt that intervening early as possible will provide the 
greatest likelihood of a response to any neuroprotective treatment, the compromise position 
however is that there will likely always be a need to identify a neuroprotective treatment that 
is also helpful in the population with clinically manifest disease, and a need to identify 
whether it is tolerated in conjunction with symptomatic agents such as L-dopa, and if it has 
any effects on the development on the major disabling milestones of PD such as freezing, 
falls, and dementia. 
Choosing the most effective dose(s) 
Doses of experimental therapies for use in human trials are often chosen to replicate plasma 
concentrations obtained from previous animal models; however, this may not necessarily 
correlate with concentrations seen in the brain and at receptor level.  Adding to the 
uncertainty is that results from various animal models are often conflicting, or may only be 
effective within a narrow range.  As no validated biomarker exists currently, it is difficult to 
titrate varying doses or ascertain the most effective dose range.  The use of adaptive trial 
designs however, can allow a large number of varying doses to be tested in the initial 
stages, without negatively affecting the longterm results.26 
 
Inhibitory development costs 
The development of a new therapy takes approximately 15 years and costs around 
$1.2billion.27  In spite of the potential commercial value of an effective disease-modifying 
therapy for PD, this area of research is considered high-risk within the pharmaceutical 
industry due to the high costs of trials and the lack of any positive results to date.  Novel 
methods being used to overcome this include using high throughput screening methods 
which utilise phenotypic cell-based drug screens.  Yeast cells engineered to express alpha 
synuclein in a way that re-captures the cellular pathology in PD have recently been used to 
screen more than 190,000 compounds for potential neuroprotective effects – which led to 
the identification of a new potential pharmaceutical target, the E3 ubiquitin ligase, and a 
novel molecule, NAB2, an N-aryl benzimidazole, which showed protective effects in three 
different PD models.28,29  High throughput screening can also be combined with a focus on 
drugs already licensed for use in humans for re-purposing to assess their effects on 
mitochondrial function  - ursodeoxycholic acid, already licensed for use in liver disease, has 
been recently identified using this method and phase 2a trials are already planned.30 
Other non-mammalian transgenic models of PD using drosophila and zebrafish are also 
being used to as low-cost, high throughput method to screen novel compounds that may 
counteract pathological mechanisms of PD.7 
 
Current neuroprotective strategies/ candidates 
Based on the various cellular mechanisms involved in the pathogenesis of PD, growing 
evidence implicates the modulation of calcium homeostasis, oxidative stress, mitochondrial 
function, autophagy, and formation and clearance of alpha-synuclein as potential targets for 
putative neuroprotective therapies (Figure 1).  These targets and the main candidates for 
neuroprotective therapies currently in clinical trial testing are summarised in Table 2.  
 
Calcium channel blockade 
It has been shown that the apparent selective vulnerability and degeneration of 
dopaminergic neurons of the SNpc in PD may be related to high energy demands 
associated with calcium influx through CaV1.3 L-type calcium channels (LTCC) during their 
autonomous pacemaking, leading to increased mitochondrial-mediated oxidative stress and 
subsequent cell death. 31  Furthermore, increased CaV1.3 subtype expression occurs in the 
cerebral cortex of early stage PD patients before the appearance of pathological changes, 
suggesting that disturbed calcium homeostasis may be an early event in the pathogenesis 
and not just a consequence of neurodegeneration, therefore offering a potentially attractive 
target for neuroprotective therapies.32  
Epidemiological data shows that patients treated with centrally acting calcium channel 
blockers may have a reduced risk of developing PD,33–35 although this remains 
controversial.36  Isradipine, licensed for the treatment of hypertension, has a high affinity for 
CaV1.3 LTCC, and while there is strong evidence of benefit in pre-clinical studies of PD;37,38 
a recent randomised trial (RCT), though not powered for efficacy, suggested only a very 
modest advantage (~1 point in the total UPDRS score) in patients treated with 10mg 
isradipine for 12 months of questionable clinical relevance.39  Furthermore, pre-clinical data 
suggests that most robust neuroprotective effects of isradipine are seen at doses much 
higher than would be tolerated in humans – possibly limiting isradipine’s therapeutic 
potential. 37  Nevertheless, a fully powered phase III trial is planned to assess efficacy of 
isradipine 10 mg in PD. Emerging candidates from pre-clinical studies including novel, highly 
selective CaV1.3 antagonists may offer more promising results in the future without 
producing side effects that accompany general antagonism of L-type calcium channels.40 
 
Oxidative stress pathways 
Evidence of oxidative damage is seen in the SN of PD patients in post mortem studies,41 and 
is thought to play an important role in the pathogenesis of PD, occurring as a result of failure 
of endogenous protective mechanisms, DA metabolism, defective mitophagy and 
accumulation of mtDNA mutations. Though previous efforts to reduce oxidative stress using 
antioxidants selegiline, rasagiline and vitamin E have not convincingly or consistently 
demonstrated disease modifying effects,42,43current clinical trials are underway investigating 
the potential of other various anti-oxidants. 
Based on epidemiological data showing that patients with high levels of serum urate, a 
natural anti-oxidant, have a 33% reduction in the risk of developing PD, 44–46 and high levels 
of urate in serum and CSF of patients with early PD are associated with slower rates of 
clinical and radiological progression,47–49 efforts are underway to investigate whether raising 
serum urate - using an orally administered precursor inosine,50 may serve as a potentially 
neuroprotective therapy. In a recent RCT, inosine was well tolerated,51 and was associated 
with a favourable rate of progression based on changes in UPDRS scores over 24 months; 
but after adjustment for baseline differences, this amounted to only ~1 point per year on total 
UPDRS scale.  Although the trial data was not powered to determine efficacy, there was no 
difference between the time to requiring dopaminergic therapy between groups, and few 
patients reached the 2 year analysis time point.  Furthermore, elevated serum urate has also 
been shown to increase the risk of hypertension, coronary heart disease, gout and stroke 
over the longer term, and these side effects are potentially problematic for older patients with 
PD, potentially limiting its ultility.52  A larger phase III trial is currently being planned. 
 
Another potential target being investigated to lessen oxidative stress is by targeting iron 
accumulation.  Levels of iron in excess of that expected in normal ageing have has been 
found in the SNpc of patients with sporadic PD and autosomal recessive juvenile 
parkinsonism53 and in vivo studies using MRI and transcranial ultrasonography show that 
increased levels of iron in the basal ganglia and SN correlate to PD motor severity54 
potentially by inducing oxidative stress and aggregation of misfolded alpha synuclein.55 
There is strong evidence from pre-clinical studies that deferiprone, a chelating agent 
licensed for the treatment of peripheral iron overload disorders, is neuroprotective.56 57 58 A 
recent delayed start design trial of deferiprone demonstrated a reduction in the UPDRS 
motor subscale in the early start group (-2.3 +/- 0.6) compared to the delayed start group 
(+1.0 +/- 0.7) which was sustained at 12 months – though improvements waned after 18 
months continuous treatment.59  Whether excessive iron represents a cause or consequence 
of dopaminergic neuronal cell death is uncertain and though efficacy results are highly 
encouraging, it remains to be seen whether observed clinical benefits in PD patients 
occurred as a result of iron chelation alone or via permissive effects of chelation on 
dopaminergic treatments.  Two further phase II/III trials are now underway (Clinical trials.gov 
identifier NCT01539837 and NCT00943748). 
Glutathione (GSH) is a tripeptide that acts as the brain’s primary anti-oxidant system (and 
also as a neurotransmitter)60  Prolonged depletion of GSH inhibits mitochondrial complex I 
activity61 and depletion of GSH is seen in the SN of PD patients,62,63 but also patients with 
incidental Lewy Body disease – suggesting that loss of GSH occurs early in the 
pathogenesis of PD.64  Previous efforts to increase GSH levels in patients with PD 
intravenously have been unsuccessful as GSH crosses the blood brain barrier via a 
saturable mechanism and is not taken up by neurons, presumably explaining why an RCT 
administering intravenous GSH to 21 PD patients failed to show any evidence of clinical 
efficacy60,65. 
N-acetylcysteine (NAC), used as a mucolytic, is an oral precursor to GSH, and decreases 
alpha-synuclein aggregation in transgenic models,66. In a pilot human trial, NAC was well 
tolerated, and could raise levels of GSH in CSF.67 Though data from transgenic models is 
encouraging, there is as yet no efficacy data in humans, so it remains to be seen whether 
orally administered NAC will offer positive effects. Notably a trial using oral administered 
NAC in patients with early Alzheimer’s disease (AD) failed to alter any primary outcome 
measures.68  Given that GSH depletion seems to occur early in the pathogenesis of PD, 
GSH replacement may be best trialled among patients at the earliest or pre-symptomatic 
stage of disease.  
Zonisamide, is a drug used for the adjunctive treatment of epilepsy thought to act via 
inhibition of voltage-gated sodium channels and calcium channels, mediating neuronal 
depolarization-induced glutamate release.69  It also enhances dopamine release and is 
licensed in Japan as an adjunctive treatment in PD to aid motor symptoms, and is currently 
being investigated in parallel for its neuroprotective potential.70  While zonisamide has 
demonstrated symptomatic benefits in doses from 25mg-100mg, pre-clinical data regarding 
neuroprotective equivalent doses is conflicting – some investigators used serum 
concentrations well above that which could be achieved with maximal human dosing,71. 
While separating proven symptomatic benefits from any neuroprotective effects may also 
prove difficult, a Phase 2 trial is currently underway (Clinical Trials.gov identifier 
NCT01766128). 
Enhancing mitochondrial function 
Considerable evidence from genetic, animal and post mortem studies implicate 
mitochondrial dysfunction in the pathogenesis of PD (see for review72) - mitochondrial toxins 
can cause parkinsonism, autosomal recessive forms of PD related to mutations in Parkin, 
DJ-1 and PINK1 impair mitochondrial autophagy and the selective vulnerability of nigro-
striatal neurons may be related to the high metabolic demands placed on the cells.  Though 
enhancing mitochondrial biogenesis to counteract the effects of neurodegeneration is a 
reasonable strategy, recent trials using mitochondrial enhancers such as creatine, co-
enzyme Q10 and MitoQ have all failed to convincingly demonstrate disease modifying 
effects. Possible reasons speculated to account for this failure include poor brain penetrance 
of the compound, patients selected with too far advanced degeneration to benefit and also 
growing evidence to suggest that mitophagy and mitochondrial calcium homeostasis may 
play larger roles in maintaining mitochondrial biogenesis than previously thought, and may 
offer better potential targets for intervention.73 
Peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α) is a protein 
that interacts with the peroxisome proliferator-activated receptor gamma (PPARy) and 
controls mitochondrial and microglial function, and acts with SIRT1 to upregulate 
mitochondrial biogenesis74 and is therefore a potentially attractive target for intervention.  
Encouraging data from pre-clinical studies of resveratrol, a SIRT1 activator, has shown it 
protects dopaminergic neurons from MPTP and 6-OHDA induced deficits in vivo, possibly 
via modulation of autophagy and pro-inflammatory pathways, and further in vivo testing is 
planned.75,76 Though no clinical data exists, there is a sufficient indication of potential benefit 
to merit further in vivo studies better elucidate the importance of these mechanisms which 
could lead to a pilot study in patients with PD. 
A recent novel high throughput screening method to identify potential compound’s that can 
rescue mitochondrial dysfunction directly in PD patient tissue identified urosdeoxycholic acid, 
which was subsequently shown to rescue mitochondrial function in parkin & LRRK2 mutant 
fibroblasts in vitro, and is neuroprotective in transgenic mouse model of AD, and has led to 
this compound being fast tracked to a phase 1 trial currently being planned.30 
 Neuroinflammation 
Inflammation is increasingly recognised as playing an important role in the pathogenesis of 
PD based on i) epidemiological studies suggesting NSAID use confers a lower risk of 
developing PD;77 ii) the presence of increased microglial activation seen in PD patients using 
PET imaging;78 iii) increased pro-inflammatory mediators seen in the SN post-mortem tissue 
of PD patients79  and an association between the HLA locus and PD risk from genome-
association studies.80Agents that target these inflammatory pathways are currently being 
investigated in clinical trials. 
Pioglitazone, licensed for use in patients with type 2 diabetes, is thought to act via activation 
of the PPARy 81 and has demonstrated anti-inflammatory-mediated neuroprotective effects 
in models of AD,82 epilepsy,83 stroke84 and ALS.85 Due to its demonstrated efficacy across 
multiple toxin animal models and influence across multiple cellular pathways,86–88 a Phase 2 
trial is currently underway (Clinical Trials.gov Identifier NCT01280123); however, its future 
potential may be limited by adverse effects and an association with the development of 
bladder cancers.89–92  It has recently been discovered that many of the metabolic effects of 
pioglitazones may occur independently of PPARy and involve binding to a complex on the 
inner mitochondrial membrane - identified as mTOT (mitochondrial target of thiazolidinones) 
directly influencing mitochondrial function93,94 and novel compounds are in early 
development in testing against models of PD, which may offer similar benefits of 
neuroprotection with limited side effects.95  
Myeloperoxidase (MPO), a heme enzyme expressed in a variety of phagocytic cells, is 
thought to play an important role in alpha synuclein-mediated toxicity.  Following alpha 
synuclein induced activation of microglia, MPO mediates production of pro-inflammatory 
molecules, promoting misfolding of wild type alpha synuclein, leading to further aggregate 
formation in unaffected neurons.96 MPO expression in microglia is found to be up regulated 
in the ventral midbrain of human PD patients and mice exposed to MPTP97 and it has been 
speculated that inhibition of MPO may slow down neurodegeneration in PD given that 
ventral midbrain dopaminergic neurons of mutant mice deficient in MPO are more resistant 
to MPTP-induced cytotoxicity.  Though a RCT of AZD3241, a novel MPO inhibitor, has 
recently been completed which demonstrated that it was well tolerated, and decreased 
plasma MPO activity,98there is no efficacy data, and the evidence from in vitro or in vivo 
studies that this particular compound may have neuroprotective effects in PD patients is still 
limited. 
Statins, as well having effects on lowering cholesterol, have marked anti-inflammatory 
effects.  In vitro studies show that simvastatin can reduce alpha-synuclein aggregation, 
inhibit the formation of TNF-alpha and peroxynitrite in activated microglia, and via 
modulation of the NMDA receptor, protect dopaminergic neurons from inflammatory 
damage, while in LPS and MPTP animal models of PD, statins prevents dopaminergic 
degeneration.99–104 Data from epidemiological data regarding statin use and risk of 
developing PD is variable, with some studies identifying a reduced incidence of PD with 
statin use105–107while others found no association108–110 or an inverse association with LDL 
cholesterol111 – though this variance is possibly explained by early studies not accounting for 
confounders such as co-morbid diabetes, and use of NSAID’s and calcium channel blockers 
which can modulate the risk of PD. However, a recent population-based study, adjusted for 
most confounders, showed that patients on continued lipophilic statin therapy had a reduced 
incidence of PD compared to people who stopped their medication, though more longitudinal 
studies are needed.112 While no clinical data of statin treatment in PD exist, there is 
promising in vivo and in vitro data highlighting potential mechanism and this should fuel 
further clinical studies.  
 
Targeting alpha synuclein: 
The pathological hallmark of PD is the presence of LB’s and Lewy neurites (LN), of which 
alpha-synuclein constitutes a major component. Substantial evidence suggests that the 
conversion of alpha-synuclein from soluble monomers to aggregated, insoluble forms is a 
key event in the pathogenesis of PD.113 Usually cleared from the cell by the ubiquitin 
proteasome or autophagy-lysosomal systems, defects of these systems have been identified 
in patients with PD.  Furthermore, post mortem studies of fetal mesencephalic brain tissue 
grafted into brains of PD patients showed evidence of LB-like inclusions in the host tissue, 
suggesting that alpha-synuclein can transfer from unaffected cells and may act as a prion 
type protein – findings which subsequently have been confirmed in vitro an in vivo13,114–117. 
Mutations and variations in the alpha-synuclein gene can cause familial PD and contribute to 
sporadic PD, and overexpression in transgenic models leads to a parkinsonian phenotype; 
and therefore targeting the formation and clearance of alpha-synuclein as therapeutic 
measures to protect against neurodegeneration are promising avenues gathering great 
interest.   
Reducing the formation of alpha-synuclein is one potential strategy and pre-clinical studies 
using small peptides, vector mediated RNAi interference and novel molecules such as 
ELN484228 that can directly block alpha synuclein aggregation118 are promising avenues 
but are still early in development.  
Another strategy  is to reduce the amount of insoluble toxic alpha-synuclein, and both active 
immunisation, or passive immunisation with monoclonal antibodies against alpha synuclein, 
given to transgenic mice overexpressing human alpha synuclein have promoted reduction 
and clearance of the protein and rescued behavioural deficits.119,120 This data has led to 2 
commercial programs i) PRX02, which is an antibody against the 9E4 C-terminus of alpha 
synuclein, has major support pledged by Roche, with a phase I trial testing the safety and 
tolerability of PRX02 commencing in healthy individuals (Clinical trials.gov NCT02095171); 
and ii) Affitope (PD01), a peptide-carrier conjugate vaccine developed to induce antibodies 
selectively against alpha synuclein, currently in phase I clinical trial testing in patients with 
PD (Clinical trials.gov NCT01568099). On a cautionary note, similar efforts using 
immunization are more advanced in AD. Previous trials targeting beta amyloid in patients 
with AD have led to early termination due to significant meningoencephalitis, and led to 
concerns regarding antibodies altering the physiological function of other synucleins or 
triggering autoimmunity, potentially exacerbating Parkinson’s pathology. However, unlike b-
amyloid, a-synuclein does not deposit in leptomeningeal and cortical blood vessels, and by 
using vaccines with short peptides that do not trigger T cell autoimmunity or cross react with 
other synucleins, these risks are theoretically lower.121 
Phosphorylation of alpha-synuclein at serine residue position 129 represents the most 
abundant form of alpha-synuclein found in LB’s and targeting these pathways underlie the 
mechanisms behind kinase inhibitors.122However, as several different kinases are capable of 
phosphorylating alpha-synuclein, a significant production of phosphor-Ser129 alpha-
synuclein would still occur with drugs targeting a single kinase alone, and therefore targeting 
enzymes such as protein phosphatase 2A (PP2A) that enhance de-phosphorylation of 
Ser129 may represent a potentially valuable therapeutic strategy.123 Metformin has recently 
been shown to lower levels of alpha-synuclein in vitro and in vivo by inhibiting mammalian 
target of rapamycin (mTOR) and enhancing PP2A activity – leading to reduced levels of 
alpha-synuclein.124 Interestingly, although epidemiological data regarding the association 
between PD and diabetes is conflicting, a recent prospective cohort study showed that Type 
2 diabetes increased the incidence of PD in a Taiwanese population almost 2-fold, which 
was exacerbated by the use of sulphonureas, but the risk was avoided by the use of 
metformin therapy.125 This emerging data is prompting further studies to investigate 
metformin’s disease modifying properties.  
Enhancing clearance of alpha-synuclein by modulating ubiquitin and lysosomal systems is 
another strategy with promising early results. The identification of heat shock proteins that 
act as "chaperones" by promoting the transfer of excessive alpha-synuclein to the ubiquitin 
and lyosomal systems for clearance has led to testing compounds that could enhance this 
pathway, such as latrepirdine, an anti-histamine, which has recently been shown to stimulate 
autophagy and reduce accumulation of α-synuclein in vitro and in vivo, and further testing is 
underway126 NAB2, a novel small molecule, has recently been shown to promote endosomal 
transport events via action on the ubiquitin ligase Rsp5/Nedd4 – “resetting” vesicle tracking 
homeostasis and reversing multiple pathological phenotypes caused by alpha-synuclein in 
vitro.28,29 
GCase, an enzyme involved in modulating lysosomal function and folding of alpha-synuclein, 
is encoded by the gene GBA1; mutations of which account for up to 25% of young onset PD 
patients,127 are associated with reduced GCase activity and increased neocortical 
accumulation of aggregates of αlpha-synuclein.128  Reduced levels of GCase activity are 
seen in the SN of patients with sporadic PD, while increased expression of alpha-synuclein 
in cell models is associated with reduced GCase activity. Therefore, targeting GCase to 
increase its activity may increase alpha-synuclein metabolism and reduce its accumulation.  
Intracerebral injection of GCase via a AAV viral vector delivery method increased activity of 
GCase and reduced accumulation of alpha-synuclein and tau and improved and reversed 
cognitive deficits,129 while ambroxol, a secretolytic agent licensed for used in the treatment of 
respiratory diseases, has been shown to act as a chaperone molecule and thus increase the 
clearance of alpha synuclein.130–132  Further testing in a Thy1-Alpha-Synuclein mouse model 
is planned.  
Though the identification of these new potential targets and preliminary results are 
encouraging, studies with these novel compounds are still very early in development.  
 
Other / uncertain / multi-pathway targeting: 
A number of neuroprotective agents currently in clinical trials have multiple or uncertain 
mechanisms that may act on several pathways related to pathological processes in PD. 
Data from in vitro and in vivo studies suggest that GM1 ganglioside, a component of 
neuronal cell membranes, affects multiple pathways implicated in the pathogenesis of PD - 
modulating intracellular calcium homeostasis, mitochondrial function, lysosomal integrity and 
preventing aggregation of alpha synuclein,133,134,135 while two subsequent RCT’s showed 
encouraging effects on motor function in PD.135,136 While purified GM1 is well tolerated, and 
has shown encouraging results through careful trial design and placebo control, the existing 
data cannot conclude that the major long term effects are more than symptomatic only. 
Given that this agent is currently produced from bovine brain tissue, GM1 has also raised 
public safety concerns and alternative methods of production using synthetic analogues or 
ovine sources are currently being investigated. 
Exenatide is a synthetic glucagon-like peptide-1 (GLP-1) agonist licensed for the treatment 
of type 2 diabetes, and improves glycaemic control via activation of the GLP-1 receptor.137  
Though their role in the CNS is unclear, GLP-1 receptor stimulation using exenatide in vitro 
has neuroprotective, anti-inflammatory and anti-apoptotic effects, and exerts neurotrophic 
effects, stimulates mitochondrial biogenesis and enhances synaptic plasticity.138,139 In views 
of these effects, exenatide has been investigated in multiple animal toxin models of PD and 
demonstrated neuroprotective and neurorestorative effects in comparable human doses 
possibly via anti-inflammatory effects140,141 or related to stimulation of neurogenesis.142 It also 
demonstrated positive effects on non-dopaminergic impairments, reversed non-motor 
behavioural impairments, and improved learning and memory performance.143,144 In a small, 
open label RCT, exenatide exposure led to a mean advantage of 7.0 points on the MDS-
UPDRS Part III which persisted after a 12 month “wash-out” period, together with 
improvements in the Mattis Dementia Rating scale and well as other non-motor areas.145,146 
While clearly encouraging, the existing trial data is open label, and thus should not be 
interpreted as proof of efficacy in PD. Furthermore there is a great deal of mechanistic 
uncertainty regarding this agent, and exenatide has also been linked to a small increased 
risk of pancreatitis in patients with diabetes.  A larger, double blind trial using a once weekly, 
long acting form of exenatide is underway (Clinical trials.gov Identifier NCT01971242).  
In view of consistent epidemiological studies suggesting a 50% reduced risk of developing 
PD in smokers,147,148 nicotine is being investigated for its potentially disease modifying 
properties.  While in vitro data suggest possible mechanism of protection - nicotine inhibits 
alpha-synuclein fibrillation and reduce oxidative stress149,150 while stimulation of the a7, a4B2 
and a4 subunit of the nicotinic Ach receptor modulates inflammatory pathways and calcium 
homeostasis,151,152 nicotine’s effects in animal models of PD are conflicting, with 
discrepancies regarding dose, level of protection and dosing regimen 153,154,155,156. Though 
conflicting results from pre-clinical trials may be explained by differences in methodology – at 
best the results are inconclusive.  Results from human trials suggest a beneficial role in 
reducing dyskinesia, but evidence for neuroprotection is as yet unconvincing. Nevertheless, 
an RCT using transdermal nicotine patches in 40 PD has been completed and results 
awaited (Clinical trials.gov NCT00873392).   
 
Neuroprotection against cognitive decline: 
Cognitive impairments have a significant impact on quality of life - dementia is common in 
the advanced stage of PD, affecting up to 80% of patients,157 and is often used as a 
milestone heralding impending residential care and mortality, but cognitive deficits are seen 
in 24% of patients even at diagnosis158, and mild cognitive impairment can occur early in the 
course of PD.2 These deficits can worsen motor disabilities seen in PD, and at all stages are 
a significant factor contributing to a poorer quality of life.2 Historically, the augmentation of 
neurotransmitter deficits have represented more relevant pharmaceutical targets for 
treatments, and currently, the acetylcholinesterase inhibitor rivastigmine is the only licensed 
therapy for cognitive symptoms in PD dementia (PDD) or Dementia with Lewy bodies (DLB), 
with evidence suggesting positive effects on cognition, behavioural disturbance and ability to 
perform activities of daily living,159 (evidence for the use of menantine in PDD is currently 
unclear and further studies are needed).  Unfortunately, acetylcholinesterase inhibitors can 
often worsen motor deficits, and only aim to correct the end result of neurodegeneration, and 
therefore do little to affect the progression of the disease.  Despite the unmet need for 
additional treatments of cognitive dysfunction in PDD and DLB, there are only two advanced 
stage clinical trials underway - donepezil, an acetylcholinesterase inhibitor, and atomoxetine, 
a selective noradrenalin reuptake inhibitor, are in phase 2/3 clinical trial testing in patients 
with PDD based on previous favourable effects on cognition and behaviour.  To date, there 
have been no clinical trials to so far investigate potential disease modifying therapies in PDD 
or DLB.   
The neuropathology underlying PDD is heterogeneous and results from previous studies 
have been variable, but it is strongly speculated that alpha-synuclein spread from the 
brainstem to limbic and neocortical structures is the major contributor to emerging dementia 
in PD.160 Therefore, it is a reasonable to assume that strategies to inhibit the formation and 
propagation of alpha-synuclein may halt cognitive and motor decline.  However, 50% of 
patients with PDD also have amyloid-B plaques and hyperphosphorylated tau-containing 
neurofibrillary tangles – usually seen in the brains of patients with AD and furthermore, this 
co-morbid pathology may act synergistically with LB’s and LN’s t and confer a worse 
prognosis.161–164  Further evidence from genetic studies lend support to suggest a link 
between tau and PD -  the H1/H1 subhaplotype of the gene that encodes tau, MAPT, has 
been associated with increased tau expression in humans,165 is associated with poor 
memory performance in PD,166 and, through recent genome-wide association studies, has 
been identified as an independent risk factor for the development of PD165167 and PDD.168 
This growing evidence supporting the role of tau in Parkinson’s disease had led some to 
speculate that targeting tau phosphorylation and formation may be of benefit in preventing 
cognitive decline, and that disease modifying therapy or strategies to target tau in AD may 
also be of benefit to a subset of patients with PDD. 
Glycogen synthase-kinase 3b (GSK-3), is an enzyme involved in the phosphorylation of tau, 
and efforts at inhibition with compounds in human trials has so far proved disappointing.  
Valproate showed no clinical efficacy in Phase 3 trials,169 while micro-doses of lithium, 
previously shown to prevent oxidative-stress-induced alpha-synuclein accumulation and 
neurodegeneration in a transgenic model of PD,170 demonstrated stabilisation of cognitive 
function in AD patients,171 but adverse effects affected subsequent follow up.  Efforts are 
further advanced with derivatives of methylene blue – a compound that has already 
demonstrated neuroprotection and reversed behavioural deficits in a rotenone model of PD 
possibly by rescuing mitochondrial function and reducing free-radical formation.172 TRx0237, 
a derivative of methylene blue, has been shown to reduce tau aggregation and inflammation 
with associated positive effects on behaviour in vivo, although studies are 
conflicting,173174while in subsequent Phase II trials of AD patients, it reduced the rate of 
cognitive decline (though no benefit was seen at high doses).175 Phase 3 trials are currently 
underway. 
Tau hyperphosporylation has been speculated to reduce stabilisation of microtubules (MT), 
exacerbating neuronal dysfunction.  In view of this, small molecule MT stabilizing drugs 
previously used in the treatment of cancers are being re-purposed to investigate their utility 
in the treatment of tauopathies. In aged transgenic mouse models with established tau 
pathology (hereby modelling a human setting) epothilone D significantly reduced tau 
pathology, prevented the loss of hippocampal neurons and synapses, and improved 
cognitive performance.176Though these results are encouraging, and may lead to the 
identification of further brain penetrating small molecule MT stabilising compounds, they are 
still very early in development and have not yet been tested in clinical trials. 
Despite the encouraging number of compounds with potentially positive effects on cognition, 
there are numerous hurdles that need to be addressed before effective disease modifying 
therapies targeting cognition can be achieved.  Identifying an appropriate target for 
intervention is required through greater understanding of the pathological process underlying 
cognitive dysfunction. Despite the large amount of evidence suggesting a role for alpha-
synuclein in the development of cognitive (and motor) symptoms, there is a marked 
heterogeneity in PDD patients – some non-demented patients with PD have been shown to 
have large amounts of cortical alpha-synuclein,177 while some demented individuals have 
demonstrated minimal cortical alpha-synuclein at post-mortem,178. Furthermore the 
interaction between AB and alpha-synuclein and correlation of cognitive function is yet to be 
elucidated. In addition, the timing of the intervention is important, as it remains to be seen 
whether halting alpha-synuclein aggregation or tau hyperphosphorylation in already 
symptomatic individuals could halt cognitive decline.  Biomarker studies have recently 
indicated PDD patients are more likely to have increased CSF levels of t-tau and decreased 
AB1-42 than in PD,179 while non-tremor dominant PD patients are more likely to develop 
dementia and manifest concurrent AB pathology180,181 and it is reasonable to assume that 
further advances in biomarker studies, incorporating CSF, neuroimaging and biochemical 
markers together with further identification of clinical subtypes of PDD patients more likely to 
develop dementia, may help clinicians and trialists select the subgroup of individuals most 
appropriate for early intervention. 
 
Conclusion 
As things stand, double blind data supporting major clinically relevant effects have not yet 
been found for any agent, but there are several drugs that have been taken to clinical trials 
based on the existing neurotoxin animal models that may yet be shown to have relevant 
neuroprotective effects. 
Many agents that appear to have beneficial effects on neuronal cell biology and may be 
useful in PD often do not survive beyond Phase 1 clinical trials because of toxicity.  
However, this hurdle can to some extent be avoided by prioritising agents already licensed 
for human use i.e. drug repositioning/repurposing.  The linked clinical trials initiative182 
launched by the Cure Parkinson’s trust is a way of identifying which licensed drugs may be 
effectively repositioned for PD and provides a rapid and cost efficient signal of effect to add 
to animal model data to allow subsequent prioritisation of larger scale investment. This said, 
agents with major effects on neurodegenerative processes may also have long-term 
consequences for e.g. inflammation and/or immunosurveillance for malignant change in 
other body tissues, and these aspects must be considered in the follow up of patients 
exposed to these drug classes. 
High throughput screening approaches are also useful to help select which of many 
thousands of compounds offers the most promise using in vitro assays e.g. measuring 
effects on alpha synuclein aggregation or mitochondrial function. Indeed it appears 
increasingly likely that direct targeting of alpha synuclein aggregation may become possible, 
while other studies demonstrate that up regulation of proteosomal or lysosomal systems, 
and/or promotion of chaperone molecules that can reduce alpha synuclein aggregation may 
be feasible, thus opening further potential new therapeutic targets. 
Efforts are underway to accurately identify an “at risk” population of PD before significant 
clinical symptoms occur – possibly an essential first step before neurodegeneration 
progresses beyond the reach of any possible neuroprotective agent. This parallels the need 
to identify a highly sensitive and specific biomarker of PD to allow high-risk individuals to be 
distinguished from people with little or no risk of developing neurodegeneration. This is of 
utmost importance not only to be confident about efficacy but also to minimise the risks of 
exposing healthy people to potential adverse events that may accompany exposure to 
potential disease modifying drugs. The progression of symptoms in PD is heavily influenced 
by factors including clinical phenotype, age, and genotype and so in future, it may be more 
helpful to classify PD and other neurodegenerative diseases as clinicopathological entities 
rather than clinical syndromes - which could help define subsets of the PD population with 
more individualised biomarkers of disease activity, more accurately gauge prognosis and aid 
selection of specific disease modifying therapies e.g. patients at higher risk of PDD. 
Although PDD can have a significant impact on quality of life, there is only a single, modestly 
effective symptomatic therapy for it and no treatments proven to slow its progression.  
Growing genetic, biochemical and pathological evidence implicates that tau and alpha-
synuclein are involved in or share converging pathways in the pathogenesis of PD, and can 
influence development of cognitive impairment in patients with PD.  These developments 
have helped identify new targets for potential disease modifying therapies and it is clear that 
agents that only aim to prevent nigro-striatal degeneration may only have limited potential or 
may need to be combined with agents that target multiple pathways.  
Many of the agents discussed have potential for further investigation – however it remains to 
be seen whether any will prove to effective neuroprotective therapies for PD. This said, the 
rate of continued advances in many areas suggests, it is reasonable to remain optimistic that 
PD may be transformed from a continually progressive, disabling disease to a chronic, more 





PubMed was searched for articles published between September 1989 and July 2014. 
MeSH search terms were “Parkinson’s disease” alone and in combination with “disease 
modification", “neuroprotection”, “clinical trials”, “alpha-synuclein”, “dementia”, “cognitive 
impairment”, “pathogenesis”, “animal models”, “mitochondrial”, “biomarkers”, “treatments”.  
Only papers in English were reviewed. Articles were selected for their relevance, with a 




Table 1. Recent high profile trials of potential neuroprotective agents in PD. While it remains 
possible that 1 or more of these approaches has beneficial neuroprotective effects for PD, 
none have data to convincingly support clinically relevant neuroprotection when 
administered in isolation according to the clinical trial protocols used. DS- Delayed Start. PA- 
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Protected DA neurons 
in MPTP and 6-OHDA 
models of PD 
Increased expression 
of BDNF, GDNF, and 
NGF183 
Phase 3 (DS)  
Inconclusive. 1mg rasagiline demonstrated 
significance but was not repeated at 2mg 
(Class 1b).  Small change in UPDRS made 









Protected DA neurons 
in MPTP and 6-OHDA 
models of PD184 
Phase 3 (PA) 
Trial involving 1,741 patients terminated 










al complex I 
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and delayed 
progression of PD in 
Earlier phase II study  - 
non-significant 
advantage in UPDRS 
scores121 
Phase 3 (PA) 
Trial terminated due to lack of efficacy over 













neurons in vitro186 
Protected DA neurons 
in MPTP models of 
Phase 3 (PA) 
Trial halted. No benefits over placebo 
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Phase 3 (PA) 
No benefit over placebo.  However, study 
had small sample size and may not have 
reached adequate levels of brain 
penetrance (Class 2b)189 
TCH346 Anti-
apoptotic 
Protected DA neurons 
in vitro and MPTP 
model18 
Phase 2  
There were no significant differences 











GDNF protects DA 
neurons in vitro and 
mouse and non-human 
primate models of 
PD190 
Intraputaminal AAV2-
neurturin injection in 
RCT superior to sham 
surgery190 
Phase 2b (PA) 
Intraputaminal and SNpc  AAV2-neurturin 
injection in RCT: No statistically significant 
efficacy on the primary endpoint (Class 2c).  
Secondary endpoint – Off periods in self-
reported motor diaries did significantly 
improve (Class 2c)191 
 
 
Fig.1 Proposed mechanisms involved in the pathogenesis of PD, with the identification of 
potential targets for intervention highlighted and the relevant drugs thought to act on these 
pathways. (1) Targeting native coils of alpha-synuclein expression, (2) upregulation of 
chaperone molecules to promote clearance of alpha-synuclein (e.g. latrepirdine, ambroxol), 
(3) targeting enzymes such as protein phosphatase 2A (PP2A) that enhance de-
phosphorylation of alpha-synuclein at Ser129 (e.g. metformin), (4) facilitation of the UPS 
system to clear unwanted alpha-synuclein (e.g.NAB2), (5) enhancing liposomal function and 
metabolism of alpha-synuclein by increasing GCase activity (e.g. resveratrol), (6) directly 
targeting toxic alpha-nuclein by active/passive immunisation (e.g. PRX02, Affitope) or 
directly blocking its aggregation (e.g. ELN484228), (7) prevent the propagation of alpha-
synuclein from affected to unaffected cells, (8) targeting Ca1.3V LTCC to reduce calcium 
influx (e.g. isradipine), (9) modulation of the NMDA receptor to limit activation of excitatory 
pathways (e.g. simvastatin), (10) targeting inflammatory pathways (e.g. pioglitazone, 
AZD3241),  (11) modulation of SIRT1 to enhance mitochondrial biogenesis and reduce 
activation of proinflammatory pathways (e.g. resveratrol), (12) reducing oxidative stress 
pathways (e.g. inosine, N-acetylcysteine, zonisamide), (13) reducing iron accumulation (e.g. 
deferiprone), (14) targeting apoptotic pathways (e.g. GCSF). 
UPS, ubiquitin-proteasome system; LTCC, L-type calcium channels; NMDA, N-methyl-D-
aspartate; ROS, reactive oxygen species; SIRT1, sirtuin1; PGC-1-alpha, peroxisome 
proliferator-activated receptor gamma coactivator 1-alpha; P-129, serine residue position 
129. 
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10mg was highest dose 
tolerated in RCT of 99 PD 
patients – modest 
advantage of UPDRS III39 
 
Inosine Antioxidant 
Raises serum urate 
levels50 
In vitro and in vivo 
evidence in 6-OHDA and 
MPTP of 
neuroprotection193 
Able to raise serum and 
CSF urate in RCT of 75 
PD patients, and 
associated with 
favourable rate of 
progression of UPDRS 
after 24 months51 
Deferiprone Anti-oxidant 
Iron chelator 
In vitro evidence for 
protection against MPP+ 
toxin related 
degeneration57 
In vivo evidence in 6-
OHDA models preserving 





RCT (DS design) of 40 
PD patients reduced iron 
levels in SN with reduced 
UPDRS III scores in ES 
group sustained at 12 
months, though waned 
after 18 months59 
NAC Antioxidant 
Precursor of GSH 
In vivo evidence in MPTP 
and transgenic mice 
overexpressing α-
synuclein, of increased 
GSH levels associated 
with prevention of DA cell 
death and motor 
abnormalities, with 
reduction of alpha-
synuclein levels in 
brain66,195,196 
 
Phase 1 trial of 12 PD 
patients raised levels of  
CSF GSH and well 
tolerated67 
Zonisamide Anti-oxidant In vitro and vivo evidence 
in 6-OHDA, MPTP and 
rotenone models in dose 
dependent manner of 
RCT of PD patients 
symptomatic improvement 
in motor function200 
neuroprotection of DN 
neurons via modulation of 
calcium homeostasis, 
enhancing GABA release 
and upregulation of 
expression of mRNA 
encoding astrocytic anti-
oxidative and 







In vivo evidence in LPS, 
rotenone and non-human 
MPTP primate models of 
improved motor and 
behavioural effects , with 
reduced microglial 
activation, DA cell 
loss86,87,201 
No clinical data  - Phase II 
trial currently underway 
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RCT of 51 PD patients – 
well tolerated, decreased 
MPO activity98 




In vivo evidence in MPTP 
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neurotropic effects with 
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improvements134 
 
RCT of 26 PD patients 
showed symptomatic 
improvements of UPDRS 
III after 5 years135 
RCT (DS design) of 77 
PD patients improved 
UPDRS III scores of ES 
group, but both groups 
worsened following 
washout136 
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effects on DA neurons, 
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PD patients showed 
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In vitro evidence to inhibit 
alpha-synuclein 
aggregation, reducing 
oxidative stress by 
modulating calcium 
homeostasis149–152 
In vivo evidence in 6-
OHDA, MPTP, rotenone 
models of halting DA cell 
loss, but conflicting 
results, and doses153–156 
 
Human trials conflicting – 
beneficial in 4 trials, no 
effect in 4 trials, 
worsening motor function 
in 1 trial150 
GCSF Anti-apoptotic 
Neurotropic factor 
In vitro evidence of 
neuroprotective of DA 
cells via activation of anti-





interaction with VEGF 
activation206  and 
modulation of pro-
inflammatory pathways.207 
In vivo evidence in MPTP 
models models, though at 
doses higher than used in 
humans208,209 
 
No clinical data yet 




In vivo evidence in 6-
OHDA models reduced 
inflammation in DA 
neurons210 
 
Phase 1 trial of 10 PD 
patients showed 
improvements in UPDRS 
III, persisting for 30 
weeks211 
RCT of 26 PD patients 
showed no effect on 
motor symptoms but 
some benefits on 
cardiovascular autonomic 
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